Long-term Follow-up

Exa‑cel Posts Complete Primary-End Point Responses in Early Pediatric Trials, With One Fatal Busulfan Event

Early ASH data point to strong efficacy in 5–11-year-olds using a CRISPR-edited autologous transplant that requires risky busulfan conditioning.